Eaglenos Sciences

Executive Summary

Eaglenos Sciences is a preclinical-stage biotechnology company headquartered in Shanghai, China, dedicated to discovering and developing targeted small molecule therapies for oncology. Founded in 2018, the company leverages structure-based drug design and translational biology to address well-validated yet challenging cancer targets, with a particular emphasis on overcoming resistance mechanisms and fulfilling unmet needs in solid tumors. Although Eaglenos has not disclosed its total funding or valuation, its focused approach on difficult oncological targets positions it as a potential player in the precision oncology space, albeit at an early stage with limited public data. Looking ahead, Eaglenos Sciences is expected to advance its lead pipeline toward clinical development. Key near-term catalysts include the nomination of a development candidate and subsequent Investigational New Drug (IND)-enabling studies, which could culminate in an IND filing with the Chinese National Medical Products Administration (NMPA). Additionally, the company may seek Series A or B financing to fund these preclinical activities and expand its pipeline. Given the preclinical stage, the conviction score is moderate, reflecting both the potential of the science and the inherent risks of early-stage drug development.

Upcoming Catalysts (preview)

• Q1 2027Lead Candidate Nomination and IND-Enabling Studies40% success
• Q2 2027Series A Financing Round50% success
• Q4 2026Publication of Preclinical Data at Major Conference60% success